CD30-Positive Neoplastic Cells Present: Clinical Trials

2 trials for CD30-Positive Neoplastic Cells Present, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 withdrawn. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Withdrawn 2
Phase 21Withdrawn 1

Follow CD30-Positive Neoplastic Cells Present: new trials by email Literature Review of CD30-Positive Neoplastic Cells Present trials Research Report on CD30-Positive Neoplastic Cells Present

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Brentuximab Vedotin, Lenalidomide, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides
Phase 1WithdrawnCity of Hope Medical Center2019-03-012019-04-30
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present
Phase 1 / Phase 2WithdrawnUniversity of Washington2018-01-032019-10-10

Narrower conditions

Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Mycosis Fungoides (1)  ·  Sezary Syndrome (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphatic Diseases (2)  ·  Lymphoma (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Lymphoma, T-Cell (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)

Interventions

Brentuximab Vedotin (2)  ·  Lenalidomide (1)  ·  ceritinib (1)

Sponsors

City of Hope Medical Center (1)  ·  University of Washington (1)

Countries

United States (2)

Top investigators

Andrei Shustov (1)  ·  Jasmine Zain, MD (1)

NIH funding

P30CA015704 (1)